Mitsubishi Tanabe Pharma America Announces Real-World Data Analysis of Disease Progression with RADICAVA (edaravone) in ALS | PR Newswire [Video]

Results from this analysis were published in the Journal of Comparative Effectiveness Research

, /PRNewswire/ — Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the publication of a retrospective analysis of real-world data in the Journal of Comparative Effectiveness Research (JCER). The study suggests that, in patients with amyotrophic lateral sclerosis (ALS), treatment with intravenous (IV) RADICAVA^® (edaravone) was associated with fewer reported disease progression milestones and deaths compared to individuals not treated with the drug.

“These data reinforce the utility of RADICAVA and build upon the growing evidence that expands our knowledge of edaravone in ALS,” said Gustavo A. Suarez Zambrano, M.D., Vice President of Medical Affairs at MTPA. “By continuing to study RADICAVA in both its IV and oral suspension forms, we aim to expand our understanding of the medication and its limitations to better support the ALS community.”

The observational analysis assessed time-to-progression milestones – such as use of canes, …